Erratum to: Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins (Molecular Diversity, (2017), 21, 3, (511-523), 10.1007/s11030-017-9731-1);Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins

Molecular Diversity

Volumn 21, Issue 3, 2017, Pages 511-523

  Speck Planche, Alejandro ^a   Cordeiro, M Natália D S ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Breast cancer; Design; Fragments; Mtk computational model; Multi target inhibitor; Quantitative contributions

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE 1; HEAT SHOCK PROTEIN 90 ALPHA; JANUS KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN INHIBITOR; PROTEIN SERINE THREONINE KINASE; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; COMPUTER MODEL; MEASUREMENT ACCURACY; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; ALGORITHM; ANTAGONISTS AND INHIBITORS; BIOLOGY; BREAST TUMOR; CHEMICAL DATABASE; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; FEMALE; HUMAN; METABOLISM; MOLECULAR MODEL; PROCEDURES; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, CHEMICAL; DRUG DESIGN; FEMALE; HUMANS; MODELS, MOLECULAR; NEOPLASM PROTEINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85012271437     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-017-9766-3     Document Type: Erratum

References (57)

1. Lovitt CJ, Shelper TB, Avery VM (2015) Evaluation of chemotherapeutics in a three-dimensional breast cancer model. J Cancer Res Clin Oncol 141:951–959. doi:10.1007/s00432-015-1950-1
2. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J (2015) Breast cancer: epidemiology and etiology. Cell Biochem Biophys 72:333–338. doi:10.1007/s12013-014-0459-6
3. DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64:52–62. doi:10.3322/caac.21203
4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40:D1100–1107. doi:10.1093/nar/gkr777
5. Mok NY, Brenk R (2011) Mining the ChEMBL database: an efficient chemoinformatics workflow for assembling an ion channel-focused screening library. J Chem Inf Model 51:2449–2454. doi:10.1021/ci200260t
6. Overington J (2009) ChEMBL. an interview with John Overington, team leader, chemogenomics at the european bioinformatics institute outstation of the european molecular biology laboratory (EMBL-EBI). J Comput Aided Mol Des 23:195–198. doi:10.1007/s10822-009-9260-9
7. Speck-Planche A, Luan F, Cordeiro MNDS (2012) Abelson tyrosine-protein kinase 1 as principal target for drug discovery against leukemias. Role of the current computer-aided drug design methodologies. Curr Top Med Chem 12:2745–2762. doi:10.2174/1568026611212240005
8. Marzaro G, Chilin A, Guiotto A, Uriarte E, Brun P, Castagliuolo I, Tonus F, Gonzalez-Diaz H (2011) Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. Eur J Med Chem 46:2185–2192. doi:10.1016/j.ejmech.2011.02.072
9. Rescigno A, Casanola-Martin GM, Sanjust E, Zucca P, Marrero-Ponce Y (2011) Vanilloid derivatives as tyrosinase inhibitors driven by virtual screening-based QSAR models. Drug Test Anal 3:176–181. doi:10.1002/dta.187
10. Le-Thi-Thu H, Casanola-Martin GM, Marrero-Ponce Y, Rescigno A, Saso L, Parmar VS, Torrens F, Abad C (2011) Novel coumarin-based tyrosinase inhibitors discovered by OECD principles-validated QSAR approach from an enlarged, balanced database. Mol Divers 15:507–520. doi:10.1007/s11030-010-9274-1
11. Casanola-Martin GM, Marrero-Ponce Y, Khan MT, Khan SB, Torrens F, Perez-Jimenez F, Rescigno A, Abad C (2010) Bond-based 2D quadratic fingerprints in QSAR studies: virtual and in vitro tyrosinase inhibitory activity elucidation. Chem Biol Drug Des 76:538–545. doi:10.1111/j.1747-0285.2010.01032.x
12. Romero-Duran FJ, Alonso N, Yanez M, Caamano O, Garcia-Mera X, Gonzalez-Diaz H (2016) Brain-inspired cheminformatics of drug-target brain interactome, synthesis, and assay of TVP1022 derivatives. Neuropharmacology 103:270–278. doi:10.1016/j.neuropharm.2015.12.019
13. Tenorio-Borroto E, Penuelas-Rivas CG, Vasquez-Chagoyan JC, Castanedo N, Prado-Prado FJ, Garcia-Mera X, Gonzalez-Diaz H (2014) Model for high-throughput screening of drug immunotoxicity—study of the anti-microbial G1 over peritoneal macrophages using flow cytometry. Eur J Med Chem 72:206–220. doi:10.1016/j.ejmech.2013.08.035
14. Speck-Planche A, Kleandrova VV, Ruso JM, Cordeiro MNDS (2016) First multitarget chemo-bioinformatic model to enable the discovery of antibacterial peptides against multiple Gram-positive pathogens. J Chem Inf Model 56:588–598. doi:10.1021/acs.jcim.5b00630
15. Speck-Planche A, Cordeiro MNDS (2015) Enabling virtual screening of potent and safer antimicrobial agents against noma: mtk-QSBER model for simultaneous prediction of antibacterial activities and ADMET properties. Mini Rev Med Chem 15:194–202. doi:10.2174/138955751503150312120519
16. Speck-Planche A, Cordeiro MNDS (2014) Chemoinformatics for medicinal chemistry: in silico model to enable the discovery of potent and safer anti-cocci agents. Future Med Chem 6:2013–2028. doi:10.4155/fmc.14.136
17. Speck-Planche A, Cordeiro MNDS (2015) Multi-target QSAR approaches for modeling protein inhibitors. Simultaneous prediction of activities against biomacromolecules present in gram-negative bacteria. Curr Top Med Chem 15:1801–1813. doi:10.2174/1568026615666150506144814
18. O’Hurley G, Daly E, O’Grady A, Cummins R, Quinn C, Flanagan L, Pierce A, Fan Y, Lynn MA, Rafferty M, Fitzgerald D, Ponten F, Duffy MJ, Jirstrom K, Kay EW, Gallagher WM (2014) Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. Histopathology 64:660–670. doi:10.1111/his.12313
19. Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schorg A, Hoogewijs D, Wenger RH, Seagroves TN, Lange CA (2013) Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res 73:5810–5820. doi:10.1158/0008-5472.CAN-13-0523
20. Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK (2012) Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res 14:R62. doi:10.1186/bcr3168
21. Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, Liu P, Zhang J (2014) The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 6:1329–1335. doi:10.3978/j.issn.2072-1439.2014.08.13
22. Baselga J (2011) Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16(Suppl 1):12–19. doi:10.1634/theoncologist.2011-S1-12
23. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF (2011) Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 144:703–718. doi:10.1016/j.cell.2011.02.003
24. Weil MK, Chen AP (2011) PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer 35:7–50. doi:10.1016/j.currproblcancer.2010.12.002
25. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstrom K, Ostman A (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175:334–341. doi:10.2353/ajpath.2009.081030
26. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC (2014) Definition of PKC-alpha, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res 74:4822–4835. doi:10.1158/0008-5472.CAN-14-0584
27. Irby RB, Yeatman TJ (2000) Role of Src expression and activation in human cancer. Oncogene 19:5636–5642. doi:10.1038/sj.onc.1203912
28. Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E, Roman-Roman S, Depil S, Cruzalegui F, Pierre A, Tucker GC, Dubois T (2013) TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS ONE 8:e63712. doi:10.1371/journal.pone.0063712
29. Maia AR, de Man J, Boon U, Janssen A, Song JY, Omerzu M, Sterrenburg JG, Prinsen MB, Willemsen-Seegers N, de Roos JA, van Doornmalen AM, Uitdehaag JC, Kops GJ, Jonkers J, Buijsman RC, Zaman GJ, Medema RH (2015) Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Ann Oncol 26:2180–2192. doi:10.1093/annonc/mdv293
30. Johansson I, Aaltonen KE, Ebbesson A, Grabau D, Wigerup C, Hedenfalk I, Ryden L (2012) Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. Genes Chromosomes Cancer 51:375–383. doi:10.1002/gcc.21922
31. Anderson AC (2003) The process of structure-based drug design. Chem Biol 10:787–797. doi:10.1016/j.chembiol.2003.09.002
32. ChemAxon (1998–2016) Standardizer (tool for structure canonicalization and transformation), J Chem v16.7.25.0, Budapest, Hungary. https://www.chemaxon.com/
33. Valdés-Martini JR, García-Jacas CR, Marrero-Ponce Y, Silveira Vaz ‘d Almeida Y, Morell C (2012) QUBILs-MAS: free software for molecular descriptors calculator from quadratic, bilinear and linear maps based on graph-theoretic electronic-density matrices and atomic weightings. v1.0, Villa Clara. http://tomocomd.com/
34. Marrero-Ponce Y (2003) Total and local quadratic indices of the molecular pseudograph’s atom adjacency matrix: applications to the prediction of physical properties of organic compounds. Molecules 8:687–726. doi:10.3390/80900687
35. Marrero-Ponce Y, Cabrera Pérez MA, Romero Zaldivar V, Ofori E, Montero LA (2003) Total and local quadratic indices of the “molecular pseudograph’s atom adjacency matrix”. Application to prediction of Caco-2 permeability of drugs. Int J Mol Sci 4:512–536. doi:10.3390/i4080512
36. Marrero-Ponce Y, Castillo-Garit JA, Olazabal E, Serrano HS, Morales A, Castanedo N, Ibarra-Velarde F, Huesca-Guillen A, Jorge E, del Valle A, Torrens F, Castro EA (2004) TOMOCOMD-CARDD, a novel approach for computer-aided ’rational’ drug design: I. Theoretical and experimental assessment of a promising method for computational screening and in silico design of new anthelmintic compounds. J Comput Aided Mol Des 18:615–634. doi:10.1007/s10822-004-5171-y
37. Montero-Torres A, Garcia-Sanchez RN, Marrero-Ponce Y, Machado-Tugores Y, Nogal-Ruiz JJ, Martinez-Fernandez AR, Aran VJ, Ochoa C, Meneses-Marcel A, Torrens F (2006) Non-stochastic quadratic fingerprints and LDA-based QSAR models in hit and lead generation through virtual screening: theoretical and experimental assessment of a promising method for the discovery of new antimalarial compounds. Eur J Med Chem 41:483–493. doi:10.1016/j.ejmech.2005.12.010
38. Marrero-Ponce Y, Medina-Marrero R, Torrens F, Martinez Y, Romero-Zaldivar V, Castro EA (2005) Atom, atom-type, and total nonstochastic and stochastic quadratic fingerprints: a promising approach for modeling of antibacterial activity. Bioorg Med Chem 13:2881–2899. doi:10.1016/j.bmc.2005.02.015
39. Marrero-Ponce Y, Iyarreta-Veitia M, Montero-Torres A, Romero-Zaldivar C, Brandt CA, Avila PE, Kirchgatter K, Machado Y (2005) Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. J Chem Inf Model 45:1082–1100. doi:10.1021/ci050085t
40. Marrero-Ponce Y, Siverio-Mota D, Galvez-Llompart M, Recio MC, Giner RM, Garcia-Domenech R, Torrens F, Aran VJ, Cordero-Maldonado ML, Esguera CV, de Witte PA, Crawford AD (2011) Discovery of novel anti-inflammatory drug-like compounds by aligning in silico and in vivo screening: the nitroindazolinone chemotype. Eur J Med Chem 46:5736–5753. doi:10.1016/j.ejmech.2011.07.053
41. Marrero-Ponce Y (2004) Linear indices of the “molecular pseudograph’s atom adjacency matrix”: definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. J Chem Inf Comput Sci 44:2010–2026. doi:10.1021/ci049950k
42. Marrero-Ponce Y, Meneses-Marcel A, Castillo-Garit JA, Machado-Tugores Y, Escario JA, Barrio AG, Pereira DM, Nogal-Ruiz JJ, Aran VJ, Martinez-Fernandez AR, Torrens F, Rotondo R, Ibarra-Velarde F, Alvarado YJ (2006) Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs. Bioorg Med Chem 14:6502–6524. doi:10.1016/j.bmc.2006.06.016
43. Casanola-Martin GM, Marrero-Ponce Y, Khan MT, Ather A, Sultan S, Torrens F, Rotondo R (2007) TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-based linear indices. Bioorg Med Chem 15:1483–1503. doi:10.1016/j.bmc.2006.10.067
44. Marrero-Ponce Y, Khan MT, Casanola Martin GM, Ather A, Sultankhodzhaev MN, Torrens F, Rotondo R (2007) Prediction of tyrosinase inhibition activity using atom-based bilinear indices. ChemMedChem 2:449–478. doi:10.1002/cmdc.200600186
45. Casanola-Martin GM, Marrero-Ponce Y, Tareq Hassan Khan M, Torrens F, Perez-Gimenez F, Rescigno A (2008) Atom- and bond-based 2D TOMOCOMD-CARDD approach and ligand-based virtual screening for the drug discovery of new tyrosinase inhibitors. J Biomol Screen 13:1014–1024. doi:10.1177/1087057108326078
46. Castillo-Garit JA, Marrero-Ponce Y, Torrens F, Garcia-Domenech R (2008) Estimation of ADME properties in drug discovery: predicting Caco-2 cell permeability using atom-based stochastic and non-stochastic linear indices. J Pharm Sci 97:1946–1976. doi:10.1002/jps.21122
47. Ibarra-Velarde F, Vera-Montenegro Y, Huesca-Guillen A, Canto-Alarcon G, Alcala-Canto Y, Marrero-Ponce Y (2008) In silico fasciolicide activity of three experimental compounds in sheep. Ann NY Acad Sci 1149:183–185. doi:10.1196/annals.1428.045
48. Talete srl (2015) DRAGON (software for molecular descriptor calculation). v6.0, Milano. http://www.talete.mi.it/products/dragon_description.htm
49. Hill T, Lewicki P (2006) STATISTICS methods and applications. A comprehensive reference for science. Industry and data mining. StatSoft, Tulsa
50. Statsoft-Team (2001) STATISTICA. Data analysis software system. v6.0, Tulsa. http://www.statsoft.com/
51. Pearson K (1895) Notes on regression and inheritance in the case of two parents. Proc R Soc Lond 58:240–242. doi:10.1098/rspl.1895.0041
52. Speck-Planche A, Cordeiro MNDS (2013) Simultaneous modeling of antimycobacterial activities and ADMET profiles: a chemoinformatic approach to medicinal chemistry. Curr Top Med Chem 13:1656–1665. doi:10.2174/15680266113139990116
53. Baskin II, Skvortsova MI, Stankevich IV, Zefirov NS (1995) On the basis of invariants of labeled molecular graphs. J Chem Inf Comput Sci 35:527–531. doi:10.1021/ci00025a021
54. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26. doi:10.1016/S0169-409X(00)00129-0
55. Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1:55–68. doi:10.1021/cc9800071
56. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623. doi:10.1021/jm020017n
57. CambridgeSoft (2003) ChemDraw Ultra. v8.0, Cambridge. http://www.cambridgesoft.com/